Hojo Y, Kumakura H, Kanai H, Iwasaki T, Ichikawa S, Kurabayashi M. Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease. Eur Heart J Cardiovasc Imaging 2016;17:492-497.
Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006;368: 1005-11.
Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the national heart and lung and blood institute aortic stenosis working group executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124:1783-91.
Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368:503-12.
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis. Results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306-14.
Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-56.
Arsenault BJ, Boekholdt SM, Dubé MP, Rhéaume E, Wareham NJ, Khaw KT et al. Lipoprotein(a) levels, genotype and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014;7:304-10.
Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63: 470-7.
Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG et al. Oxidized phospholipids, lipoprotein(a) and progression of aortic valve stenosis. J Am Coll Cardiol 2015;66:1236-46.
Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012;60: 716-21.
Bouchareb R, Mahmut A, Nsaibia MJ, Boulanger MC, Dahou A, Lépine JL et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 2015;132: 677-90.
Hung MY, Witztum JL, Tsimikas S. New therapeutic targets for calcific aortic valve stenosis: The lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis. J Am Coll Cardiol 2014;63:478-80.
Tsimikas S, Viney NJ, Hughes SG, SingletonW, Graham MJ, Baker BF et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebocontrolled phase 1 study. Lancet 2015;386:1472-83.
